Anbio Biotechnology (NNNN) Equity Average (2024)

Anbio Biotechnology (NNNN) recorded quarterly Equity Average of $16.0 million in Q4 2024.

Anbio Biotechnology (NNNN) Equity Average (2024) Analysis & Trends

Anbio Biotechnology's Equity Average history runs 1 years deep, the most recent figure standing at $16.0 million for Q4 2024.

In Q4 2024, Equity Average changed N/A year-over-year to $16.0 million; the TTM figure through Dec 2024 stood at $16.0 million (changed N/A YoY), while the FY2025 annual figure was $23.7 million, up 47.91% from the prior year.
Equity Average was $16.0 million for Q4 2024 at Anbio Biotechnology.
In the past five years, Equity Average ranged from a high of $16.0 million in Q4 2024 to a low of $16.0 million in Q4 2024.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Equity Avg. (Qtr)
1	Intuitive Surgical	148.09 Bn	143.69 Bn	1.83 Bn	17.71 Bn
2	Becton Dickinson	41.00 Bn	39.99 Bn	2.15 Bn	20.42 Bn
3	Medline	30.38 Bn	36.22 Bn	1.84 Bn	11.00 Bn
4	Resmed	28.22 Bn	26.56 Bn	890.98 Mn	6.41 Bn
5	West Pharmaceutical Services	23.72 Bn	23.19 Bn	296.40 Mn	3.08 Bn
6	Solventum	13.33 Bn	13.33 Bn	1.10 Bn	5.01 Bn
7	Cooper Companies	13.12 Bn	12.99 Bn	735.40 Mn	8.30 Bn
8	Align Technology	12.86 Bn	11.80 Bn	736.59 Mn	4.10 Bn
9	Baxter International	10.51 Bn	8.47 Bn	891.00 Mn	6.07 Bn
10	Anbio Biotechnology	720.59 Mn	708.69 Mn	-	-

Historic Data

Download Data

Date	Value
Dec 31, 2024	16.01 Mn